Skip to main content Skip to navigation
BV510 Mouse Anti-Human CD66
BV510 Mouse Anti-Human CD66

Multiparameter flow cytometric analysis using BD OptiBuild™ BV510 Mouse Anti-Human CD66 antibody (Cat. No. 740185) on human peripheral blood.  Flow cytometry was performed using a BD LSRFortessa™ X-20  Flow Cytometer System.

Multiparameter flow cytometric analysis using BD OptiBuild™ BV510 Mouse Anti-Human CD66 antibody (Cat. No. 740185) on human peripheral blood.  Flow cytometry was performed using a BD LSRFortessa™ X-20  Flow Cytometer System.

Product Details
Down Arrow Up Arrow


BD OptiBuild™
CEA, carcinoembryonic antigen, CD66a, CD66c, CD66d, CD66e
Human (Tested in Development)
Mouse BALB/c IgG2a, κ
Human Breast Carcinoma Cells
Flow cytometry (Qualified)
0.2 mg/ml
VI MA87
AB_2739938
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BV510 under optimal conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions.  More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).

Product Notices

  1. This antibody was developed for use in flow cytometry.
  2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  3. Researchers should determine the optimal concentration of this reagent for their individual applications.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
  9. BD Horizon Brilliant Violet 510 is covered by one or more of the following US patents: 8,575,303; 8,354,239.
740185 Rev. 2
Antibody Details
Down Arrow Up Arrow
B1.1/CD66

The B1.1 monoclonal antibody binds to several glycosylphosphatidylinositol-anchored glycoproteins present on granulocytes and epithelial cells. As reported in the Sixth International Workshop and Conference on Human Leucocyte Differentiation Antigens, the B1.1 antibody recognized CD66a (CEACAM1), CD66c (CEACAM6), CD66d (CEACAM3) and CD66e (CEACAM5). CD66 antigens belong to the carcinoembryonic antigen (CEA) family of molecules that are closely related to the immunoglobulin superfamily of glycoproteins. Studies on CD66 molecules suggest a potential adhesion function in vivo. These molecules exhibit both homophilic and heterophilic adhesion. CEA family members may be involved in transmembrane signaling and activation of neutrophils.

The antibody was conjugated to BD Horizon™ BV510 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 405-nm and Em Max at 510-nm, BD Horizon BV510 can be excited by the violet laser and detected in the BD Horizon V500 (525/50-nm) filter set. BD Horizon BV510 conjugates are useful for the detection of dim markers off the violet laser.

740185 Rev. 2
Format Details
Down Arrow Up Arrow
BV510
The BD Horizon Brilliant Violet™ 510 (BV510) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This polymer-technology based dye with an excitation maximum (Ex Max) at 327-nm / 405-nm and an emission maximum (Em Max) at 512-nm. BV510, driven by BD innovation, is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 510-nm (e.g., a 525/50 bandpass filter). The dye can be excited by the UV (355-nm) laser resulting in cross-laser excitation and spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
BV510
Violet 405 nm
327 nm, 405 nm
512 nm
740185 Rev.2
Citations & References
Down Arrow Up Arrow

Development References (10)

  1. Colcher D, Hand PH, Nuti M, Schlom J. Differential binding to human mammary and nonmammary tumors of monoclonal antibodies reactive with carcinoembryonic antigen. Cancer Invest. 1983; 1(2):127-138. (Immunogen: Immunohistochemistry, Immunoprecipitation, Radioimmunoassay). View Reference
  2. Kishimoto T. Tadamitsu Kishimoto .. et al., ed. Leucocyte typing VI : white cell differentiation antigens : proceedings of the sixth international workshop and conference held in Kobe, Japan, 10-14 November 1996. New York: Garland Pub.; 1997.
  3. Kuroki M, Arakawa F, Matsuo Y, et al. Molecular cloning of nonspecific cross-reacting antigens in human granulocytes. J Biol Chem. 1991; 266(18):11810-11817. (Biology). View Reference
  4. Kuroki M, Matsuo Y, Matsuoka Y. CD66 family Workshop: Reactivity of the CD66 Panel of monoclonal antibodies with soluble and membrane bound recombinant CD66 antigens. In: Kishimoto T. Tadamitsu Kishimoto .. et al., ed. Leucocyte typing VI : white cell differentiation antigens : proceedings of the sixth international workshop and conference held in Kobe, Japan, 10-14 November 1996. New York: Garland Pub.; 1997:1009-1010.
  5. Maruyama K, Selmani Z, Ishii H, et al. Flt3 ligand enhances anti-tumor effects of antibody therapeutics. Int Immunopharmacol. 2012; 12:481-486. (Clone-specific: Flow cytometry). View Reference
  6. Nagel G, Grunert F, Kuijpers TW, Watt SM, Thompson J, Zimmermann W. Genomic organization, splice variants and expression of CGM1, a CD66-related member of the carcinoembryonic antigen gene family. Eur J Biochem. 1993; 214(1):27-35. (Biology). View Reference
  7. Schlossman SF. Stuart F. Schlossman .. et al., ed. Leucocyte typing V : white cell differentiation antigens : proceedings of the fifth international workshop and conference held in Boston, USA, 3-7 November, 1993. Oxford: Oxford University Press; 1995.
  8. Skubitz KM, Grunert F, Jantscheff P, Kuroki M, Skubitz APN. CD66 family Workshop Panel report. In: Kishimoto T. Tadamitsu Kishimoto .. et al., ed. Leucocyte typing VI : white cell differentiation antigens : proceedings of the sixth international workshop and conference held in Kobe, Japan, 10-14 November 1996. New York: Garland Pub.; 1997:992-1000.
  9. Szpak CA, Johnston WW, Lottich SC, Kufe D, Thor A, Schlom J. Patterns of reactivity of four novel monoclonal antibodies (B72.3, DF3, B1.1 and B6.2) with cells in human malignant and benign effusions. Acta Cytol. 1984; 28(4):356-367. (Clone-specific: Immunohistochemistry). View Reference
  10. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal. 1991; 5(5):344-366. (Biology). View Reference
View All (10) View Less
740185 Rev. 2

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.